HGC Investment Management’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Sell
150,000
-1,080,980
-88% -$10.8M 0.3% 92
2026
Q1
$12.3M Hold
1,230,980
2.72% 4
2025
Q4
$12.2M Buy
+1,230,980
New +$12.2M 2.58% 6

Other funds holding DMII

HGC Investment Management's DMII Position: Q2 2026 in Review

HGC Investment Management reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 88% in Q2 2026, selling an estimated $10.8M and leaving 150,000 shares worth $1.51M. The position accounts for 0.3% of the portfolio, ranked #92.

HGC Investment Management first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.3M in Q1 2026. 68 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • HGC Investment Management held 150,000 shares of Drugs Made In America Acquisition II Corp worth $1.51M as of Q2 2026.
  • HGC Investment Management sold 1,080,980 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $10.8M.
  • Drugs Made In America Acquisition II Corp made up 0.3% of HGC Investment Management's portfolio in Q2 2026, its #92 holding.
  • HGC Investment Management first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • HGC Investment Management's Drugs Made In America Acquisition II Corp position peaked at $12.3M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on HGC Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.